The city of Charleston, South Carolina, currently has 6 active clinical trials seeking participants for Alzheimer's Disease research studies.
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/19/2024
Locations: Ralph H. Johnson VA Health Care System, Charleston, South Carolina
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Alzheimer's Disease Neuroimaging Initiative 4
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/19/2024
Locations: Ralph H. Johnson VA Health Care System, Charleston, South Carolina
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Dementia
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Recruiting
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease. The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason and safety and tolerability in subjects wit... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/17/2024
Locations: Clinical Trial Site, Charleston, South Carolina
Conditions: Psychosis Associated With Alzheimer's Disease
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
Recruiting
This is a phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to phase 2B. In phase 2A there will be adaptive dosing evaluation of three dose levels with exposure to varoglutamstat or placebo for a minimum of 24 weeks, with preliminary evaluation of both cognitive function and pharmacodynamic changes on EEG spectral analysis in approximately 180 participants. In the event that the stage gate for phase 2B is reached, the... Read More
Gender:
All
Ages:
Between 50 years and 89 years
Trial Updated:
04/26/2024
Locations: Lowcountry Center for Veterans Research (LCVR), Charleston, South Carolina
Conditions: Alzheimer Disease
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
Recruiting
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
02/12/2024
Locations: GSK Investigational Site, Charleston, South Carolina
Conditions: Alzheimer's Disease
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Recruiting
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). This study will also evaluate the long-term safety and tolerabili... Read More
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
02/06/2024
Locations: Ralph H. Johnson VA Medical Center, Charleston, South Carolina +1 locations
Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease